
“Breaking Boundaries: Allarity Therapeutics Expands Phase 2 Clinical Trial for Stenoparib in Advanced Ovarian Cancer”
Allarity Therapeutics Announces Phase 2 Clinical Development Plans for Stenoparib in Ovarian Cancer Boston (February 6, 2025) Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) is a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response…